{"pmid":32407807,"title":"Could Patients With Inflammatory Bowel Disease Treated with Immunomodulators or Biologics Be at Lower Risk for Severe Forms of Covid-19?","text":["Could Patients With Inflammatory Bowel Disease Treated with Immunomodulators or Biologics Be at Lower Risk for Severe Forms of Covid-19?","Gastroenterology","Macaluso, Fabio Salvatore","Orlando, Ambrogio","32407807"],"journal":"Gastroenterology","authors":["Macaluso, Fabio Salvatore","Orlando, Ambrogio"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407807","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1053/j.gastro.2020.05.026","topics":["Treatment"],"weight":1,"_version_":1666802845518659584,"score":9.490897,"similar":[{"pmid":32220656,"title":"Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.","text":["Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.","Lancet Gastroenterol Hepatol","Zingone, Fabiana","Savarino, Edoardo Vincenzo","32220656"],"journal":"Lancet Gastroenterol Hepatol","authors":["Zingone, Fabiana","Savarino, Edoardo Vincenzo"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220656","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/S2468-1253(20)30085-6","topics":["Diagnosis"],"weight":1,"_version_":1666138492260843520,"score":50.055668},{"pmid":32215548,"pmcid":"PMC7184365","title":"Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","text":["Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.","J Crohns Colitis","Monteleone, Giovanni","Ardizzone, Sandro","32215548"],"abstract":["Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia."],"journal":"J Crohns Colitis","authors":["Monteleone, Giovanni","Ardizzone, Sandro"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215548","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa061","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490514964482,"score":44.963127},{"pmid":32303756,"pmcid":"PMC7188162","title":"Impact of anti-tnfalpha antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases.","text":["Impact of anti-tnfalpha antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases.","J Crohns Colitis","Tursi, Antonio","Papa, Alfredo","32303756"],"journal":"J Crohns Colitis","authors":["Tursi, Antonio","Papa, Alfredo"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303756","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1093/ecco-jcc/jjaa076","topics":["Treatment"],"weight":1,"_version_":1666138491115798528,"score":44.65844},{"pmid":32314483,"title":"COVID-19 and psoriasis: Should we fear for patients treated with biologics?","text":["COVID-19 and psoriasis: Should we fear for patients treated with biologics?","The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midst of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision.","Dermatol Ther","Amerio, Paolo","Prignano, Francesca","Giuliani, Federica","Gualdi, Giulio","32314483"],"abstract":["The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midst of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision."],"journal":"Dermatol Ther","authors":["Amerio, Paolo","Prignano, Francesca","Giuliani, Federica","Gualdi, Giulio"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314483","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dth.13434","keywords":["covid-19","sars","biologics","psoriasis","therapy"],"topics":["Treatment"],"weight":1,"_version_":1666138493540106240,"score":43.271114},{"pmid":32380023,"pmcid":"PMC7198187","title":"Immunomodulation in COVID-19.","text":["Immunomodulation in COVID-19.","Lancet Respir Med","Ingraham, Nicholas E","Lotfi-Emran, Sahar","Thielen, Beth K","Techar, Kristina","Morris, Rachel S","Holtan, Shernan G","Dudley, R Adams","Tignanelli, Christopher J","32380023"],"journal":"Lancet Respir Med","authors":["Ingraham, Nicholas E","Lotfi-Emran, Sahar","Thielen, Beth K","Techar, Kristina","Morris, Rachel S","Holtan, Shernan G","Dudley, R Adams","Tignanelli, Christopher J"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380023","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/S2213-2600(20)30226-5","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097276702720,"score":43.028133}]}